192 related articles for article (PubMed ID: 10785593)
1. Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma.
Coley HM; Verrill MW; Gregson SE; Odell DE; Fisher C; Judson IR
Eur J Cancer; 2000 May; 36(7):881-8. PubMed ID: 10785593
[TBL] [Abstract][Full Text] [Related]
2. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
[TBL] [Abstract][Full Text] [Related]
3. Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in acute myeloid leukaemia.
Grey M; Borg AG; Wood P; Burgess R; Fisher A; Yin JA
Leuk Res; 1997 Sep; 21(9):867-74. PubMed ID: 9393602
[TBL] [Abstract][Full Text] [Related]
4. Expression of P-glycoprotein, multidrug resistance-associated protein 1, and lung resistance-related protein in human soft tissue sarcomas before and after hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan.
Komdeur R; Plaat BE; Hoekstra HJ; Molenaar WM; Hollema H; van den Berg E; Mastik MF; van der Graaf WT
Cancer; 2001 May; 91(10):1940-8. PubMed ID: 11346877
[TBL] [Abstract][Full Text] [Related]
5. Enhancement by recombinant human interferon alfa of the reversal of multidrug resistance by MRK-16 monoclonal antibody.
Fogler WE; Pearson JW; Volker K; Ariyoshi K; Watabe H; Riggs CW; Wiltrout RH; Longo DL
J Natl Cancer Inst; 1995 Jan; 87(2):94-104. PubMed ID: 7707396
[TBL] [Abstract][Full Text] [Related]
6. Flow cytometric analysis of P-glycoprotein expression and drug efflux in human soft tissue and bone sarcomas.
Kunikane H; Zalupski MM; Ramachandran C; KuKuruga MA; Lucas D; Ryan JR; Krishan A
Cytometry; 1997 Aug; 30(4):197-203. PubMed ID: 9298839
[TBL] [Abstract][Full Text] [Related]
7. Expression of multidrug resistance proteins, P-gp, MRP1 and LRP, in soft tissue sarcomas analysed according to their histological type and grade.
Komdeur R; Plaat BE; van der Graaf WT; Hoekstra HJ; Hollema H; van den Berg E; Zwart N; Scheper RJ; Molenaar WM
Eur J Cancer; 2003 May; 39(7):909-16. PubMed ID: 12706359
[TBL] [Abstract][Full Text] [Related]
8. Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in chronic lymphocytic leukaemia.
Grey MR; Burgess R; Fisher A; Yin JA
Leuk Res; 1999 Jan; 23(1):29-35. PubMed ID: 9933132
[TBL] [Abstract][Full Text] [Related]
9. Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia?
Broxterman HJ; Sonneveld P; Pieters R; Lankelma J; Eekman CA; Loonen AH; Schoester M; Ossenkoppele GJ; Löwenberg B; Pinedo HM; Schuurhuis GJ
Leukemia; 1999 Feb; 13(2):258-65. PubMed ID: 10025900
[TBL] [Abstract][Full Text] [Related]
10. Multidrug resistance phenotype in high grade soft tissue sarcoma: correlation of P-glycoprotein immunohistochemistry with pathologic response to chemotherapy.
Jimenez RE; Zalupski MM; Frank JJ; Du W; Ryan JR; Lucas DR
Cancer; 1999 Sep; 86(6):976-81. PubMed ID: 10491523
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of P-glycoprotein expression in soft tissue sarcomas of the extremities.
Serra M; Scotlandi K; Manara MC; Maurici D; Benini S; Sarti M; Nini G; Barbanti-Brodano G; Baldini N
Cytotechnology; 1996; 19(3):253-6. PubMed ID: 8862015
[TBL] [Abstract][Full Text] [Related]
12. Drug resistance studies using fresh human ovarian carcinoma and soft tissue sarcoma samples.
Coley HM
Keio J Med; 1997 Sep; 46(3):142-7. PubMed ID: 9339643
[TBL] [Abstract][Full Text] [Related]
13. Synovial sarcoma: immunohistochemical expression of P-glycoprotein and glutathione S transferase-pi and clinical drug resistance.
Lopes JM; Bruland OS; Bjerkehagen B; Silva MC; Holm R; Pettersen EO; Solheim OP; Sobrinho-Simões M; Nesland JM
Pathol Res Pract; 1997; 193(1):21-36. PubMed ID: 9112270
[TBL] [Abstract][Full Text] [Related]
14. Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines.
Roovers DJ; van Vliet M; Bloem AC; Lokhorst HM
Leuk Res; 1999 Jun; 23(6):539-48. PubMed ID: 10374847
[TBL] [Abstract][Full Text] [Related]
15. MRP1 overexpression determines poor prognosis in prospectively treated patients with localized high-risk soft tissue sarcoma of limbs and trunk wall: an ISG/GEIS study.
Martin-Broto J; Gutierrez AM; Ramos RF; Lopez-Guerrero JA; Ferrari S; Stacchiotti S; Picci P; Calabuig S; Collini P; Gambarotti M; Bague S; Dei Tos AP; Palassini E; Luna P; Cruz J; Cubedo R; Martinez-Trufero J; Poveda A; Casali PG; Fernandez-Serra A; Lopez-Pousa A; Gronchi A
Mol Cancer Ther; 2014 Jan; 13(1):249-59. PubMed ID: 24145283
[TBL] [Abstract][Full Text] [Related]
16. Evidence for a constitutive, verapamil-sensitive, non-P-glycoprotein multidrug resistance phenotype in malignant glioma that is unaltered by radiochemotherapy in vivo.
Rieger L; Rieger J; Winter S; Streffer J; Esser P; Dichgans J; Meyermann R; Weller M
Acta Neuropathol; 2000 May; 99(5):555-62. PubMed ID: 10805101
[TBL] [Abstract][Full Text] [Related]
17. Liposome-encapsulated daunorubicin for PGP-related multidrug resistance.
Michieli M; Damiani D; Ermacora A; Masolini P; Michelutti A; Michelutti T; Russo D; Pea F; Baccarani M
Br J Haematol; 1999 Jul; 106(1):92-9. PubMed ID: 10444168
[TBL] [Abstract][Full Text] [Related]
18. MDR1 gene expression: evaluation of its use as a molecular marker for prognosis and chemotherapy of bone and soft tissue sarcomas.
Stein U; Shoemaker RH; Schlag PM
Eur J Cancer; 1996 Jan; 32A(1):86-92. PubMed ID: 8695249
[TBL] [Abstract][Full Text] [Related]
19. SDZ PSC-833--a novel potent in vitro chemosensitizer in multiple myeloma.
Jonsson B; Nilsson K; Nygren P; Larsson R
Anticancer Drugs; 1992 Dec; 3(6):641-6. PubMed ID: 1363199
[TBL] [Abstract][Full Text] [Related]
20. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
Schuurhuis GJ; Broxterman HJ; Ossenkoppele GJ; Baak JP; Eekman CA; Kuiper CM; Feller N; van Heijningen TH; Klumper E; Pieters R
Clin Cancer Res; 1995 Jan; 1(1):81-93. PubMed ID: 9815890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
